Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic autoantibodies are antibodies produced by the immune system that mistakenly target and bind to the body’s own proteins, cells, or tissues (self-antigens), leading to inflammation, tissue injury, and a range of autoimmune diseases. They are often high-affinity IgG molecules that arise due to a breakdown in self-tolerance mechanisms and can cause disease through various mechanisms, including disrupting normal protein function, forming immune complexes, activating complement, and inducing altered signaling pathways. Their identification is crucial for diagnosis, monitoring disease progression, and developing targeted therapies for autoimmune disorders.
Varies depending on the specific autoantibody and its target. Examples include: B cell depletion, complement inhibition, immunosuppression, neutralization of autoantibody, blockade of receptor signaling.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic Autoantibody (N/A).